Across TCGA pan-cancer cohorts, ZNF785 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated ZNF785 data layer compared with 7 for mutation status.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ZNF785 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF785 expression acts as an unfavorable survival marker, although some lineages such as HNSC and THYM show a favorable association.
LIHC, HNSC, and THYM are the cancer types where ZNF785 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.